Robert I. Haddad

Overview

Best Publications

• Comprehensive genomic characterization of head and neck squamous cell carcinomas

  Michael S. Lawrence;Carrie Sougnez;Lee Lichtenstein;Kristian Cibulskis

  4612
  Citations

• Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

  Robert L. Ferris;George Blumenschein;Jerome Fayette;Joel Guigay

  4492
  Citations

• Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.

  Marshall R. Posner;Diane M. Hershock;Cesar R. Blajman;Elizabeth Mickiewicz

  2007
  Citations

• Recent Advances in Head and Neck Cancer

  Robert I. Haddad;Dong M. Shin

  1104
  Citations

• Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

  Laura Q.M. Chow;Robert Haddad;Shilpa Gupta;Amit Mahipal

  970
  Citations

• Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

  David G. Pfister;Sharon Spencer;David Adelstein;Douglas Adkins

  921
  Citations

• Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.

  Robert Haddad;Robert Haddad;Anne O'Neill;Guilherme Rabinowits;Roy Tishler

  833
  Citations

• Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

  Robert L. Ferris;George Blumenschein;Jerome Fayette;Joel Guigay

  778
  Citations

• Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

  Joshua Bauml;Tanguy Y. Seiwert;David G. Pfister;Francis Worden

  634
  Citations

• Head and Neck Cancers, Version 2.2014

  David G. Pfister;Sharon Spencer;David M. Brizel;Barbara Burtness

  628
  Citations

• Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial

  M. R. Posner;J. H. Lorch;O. Goloubeva;M. Tan

  545
  Citations

• NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018

  A. Dimitrios Colevas;Sue S. Yom;David G. Pfister;Sharon Spencer

  541
  Citations

• Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.

  Jochen H Lorch;Olga Goloubeva;Robert I Haddad;Kevin Cullen

  512
  Citations

• Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors

  Diana Miao;Diana Miao;Claire A. Margolis;Claire A. Margolis;Natalie I. Vokes;Natalie I. Vokes;David Liu;David Liu

  511
  Citations

• Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

  Jean Pascal H Machiels;Robert I. Haddad;Jérôme Fayette;Lisa F. Licitra

  469
  Citations

• Characterization of HPV and host genome interactions in primary head and neck cancers.

  Michael Parfenov;Chandra Sekhar Pedamallu;Nils Gehlenborg;Nils Gehlenborg;Samuel S. Freeman

  448
  Citations

• Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

  Kevin J Harrington;Robert L Ferris;George Blumenschein;A Dimitrios Colevas

  437
  Citations

• Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

  Nancy Y Lee;Robert L Ferris;Amanda Psyrri;Robert I Haddad

  412
  Citations

• Head and Neck Cancers

  David G. Pfister;Kie Kian Ang;David M. Brizel;Barbara A. Burtness

  400
  Citations

• Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.

  Ranee Mehra;Ranee Mehra;Tanguy Y. Seiwert;Shilpa Gupta;Shilpa Gupta;Jared Weiss

  381
  Citations